Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 21, 2008. The report details a corporate action regarding the application for block listings of ordinary shares with the UK Listing Authority and the London Stock Exchange.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notification of a share listing application and does not contain financial performance data.
Material Changes
The material change reported is the application to list 20,000,000 Ordinary shares of 25p each on the London Stock Exchange. These shares will rank equally with existing issued shares upon issuance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the mechanics of the share listing application.
Important Facts for Investors
- Total Shares Listed: 20,000,000 Ordinary shares of 25p each.
- Share Breakdown:
- 10,000,000 shares under the GlaxoSmithKline Share Option Plan - ADS.
- 5,000,000 shares under the GlaxoSmithKline Share Option Plan - Ordinary shares.
- 5,000,000 shares under the GlaxoSmithKline Savings Related Share Option Scheme.
- Share Status: New shares will rank equally with existing issued shares.
- Signatory: Victoria Whyte, Authorised Signatory.